Tralokinumab

The European Medicines Agency has recommended extending the use of Adtralza in the European Union to adolescents with moderate to severe atopic dermatitis, according to a LEO Pharma press release.

Tralokinumab led to early and clinically meaningful improvements in patient-reported outcomes for moderate to severe atopic dermatitis compared with placebo, according to a study published in Annals of Allergy, Asthma & Immunology.

Progressive improvement in atopic dermatitis symptoms was found with continued tralokinumab plus topical corticosteroids, according to a study.

For some atopic dermatitis patients treated with tralokinumab who do not reach clear or almost clear skin, clinically meaningful results can still occur.

BOSTON — Long-term use of tralokinumab showed sustained atopic dermatitis improvement with no new safety signals, according to a poster presented at the American Academy of Dermatology Annual Meeting.

Treatment with tralokinumab significantly improved symptoms among adolescents with moderate to severe atopic dermatitis, according to a study presented at the Western Society of Allergy, Asthma & Immunology Annual Scientific Meeting.

The FDA has approved tralokinumab for the treatment of moderate to severe atopic dermatitis, LEO Pharma announced in a press release.

Tralokinumab significantly improved atopic dermatitis in adolescents, according to phase 3 trial results presented at the 2021 Fall Clinical Dermatology Conference.

In this video, Emma Guttman-Yassky, MD, PhD, Waldman Professor and System Chair in The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, discusses how dermatologists can differentiate atopic dermatitis from other skin conditions that may mimic its symptoms.

Amy S. Paller, MD, of Northwestern University Feinberg School of Medicine, discussed recent developments in atopic dermatitis and what’s coming up in the pipeline.